Study identifier:NIS-OBR-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Epidemiologic study of KRAS mutation in Brazilian patients with advanced or metastatic Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
N/A
No
-
All
112
Observational
N/A
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
Laboratorio Progenetica
The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lung cancer (NSCLC).
Location
Location
Santo André, Brazil
Location
Porto Alegre, Brazil
Location
Belo Horizonte, Brazil
Location
São Paulo, Brazil
Location
Rio de Janeiro, Brazil
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.